Data Article

Speckle tracking echocardiography data in Brugada syndrome patients

Esther Scheirlynck a, b, *, Sophie Van Malderen b, Andreea Motoc a, b, Øyvind H. Lie c, d, e, Carlo de Asmundis a, Juan Sieira a, Gian-Battista Chierchia a, Pedro Brugada a, Bernard Cosyns a, b, Steven Droogmans a, b

a Department of Cardiology, Centrum voor Hart- en Vaatziekten, Universitair Ziekenhuis Brussel, Brussels, Belgium
b Life Sciences and Medicine, Vrije Universiteit Brussel, Brussels, Belgium
c Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
d Center for Cardiological Innovation, Oslo University Hospital, Rikshospitalet, Oslo, Norway
e Institute for Clinical Medicine, University of Oslo, Oslo, Norway

ARTICLE INFO

Article history:
Received 29 June 2019
Received in revised form 18 July 2019
Accepted 22 July 2019
Available online 29 July 2019

Keywords:
Brugada syndrome
Inducible
Mechanical dispersion
Strain
Speckle tracking echocardiography
Spontaneous type 1

ABSTRACT

Brugada syndrome is characterized by typical electrocardiogram changes and a high risk for sudden cardiac death (Priori et al., 2013). In addition to the well known electrical substrate, morphological and functional alterations appeared to be present in a subset of the Brugada syndrome patients (Catalano et al., 2009). Echocardiographic speckle tracking enables us to detect subtle contraction alterations (Smiseth et al., 2016). We performed transthoracic echocardiography with speckle tracking analysis in 82 healthy controls and 175 Brugada syndrome patients. Main findings are presented and discussed in the article “Contraction alterations in Brugada syndrome; association with life-threatening ventricular arrhythmias” (Scheirlynck et al., 2019). This related Data article contains segmental longitudinal strain values for RV and LV, and the comparison of echocardiographic parameters between Brugada syndrome patients with spontaneous and drug-induced type 1 pattern and between patients with and without ventricular arrhythmia inducibility during electrophysiological study.

© 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

DOI of original article: https://doi.org/10.1016/j.ijcard.2019.06.074.

* Corresponding author. Centrum voor Hart- en Vaatziekten, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium.
E-mail address: esther.scheirlynck@vub.be (E. Scheirlynck).

https://doi.org/10.1016/j.dib.2019.104330
2352-3409/© 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Brugada syndrome is a heritable channelopathy characterized by typical electrocardiogram changes and a high risk for sudden cardiac death [1, 2]. Initially considered as a purely electrical disease, the use of cardiac imaging in Brugada syndrome only gained interest recently. Mild morphological and functional abnormalities affecting the right ventricular outflow tract [3–8] - and to a lesser extent the right ventricle (RV) and the left ventricle (LV) [9–11] – were observed. Echocardiographic speckle tracking can reveal subtle alterations in myocardial contraction patterns [12]. We acquired transthoracic echocardiography in 82 healthy controls and 175 Brugada syndrome patients [13]. Speckle tracking analysis was performed for the left (16 segments) and right ventricle (3 segments) (Fig. 1). Segmental longitudinal strain values of healthy individuals and Brugada syndrome patients are reported and...
compared in Table 1. The raw segmental strain values for Brugada syndrome patients are reported in the supplementary file.

Mechanical dispersion, which is defined as the standard deviation of the time-interval from onset of the QRS-complex until the peak myocardial shortening in the 16 left ventricle, 3 right ventricle free wall segments.

**Table 1.** Segmental RVLS and LVLS values in healthy individuals and BrS patients. Comparison was performed by Student’s t-test.

| Segment               | Controls, n = 82 | BrS, n = 175 | p-value |
|-----------------------|------------------|--------------|---------|
| RVLS apical, % (±SD)  | –22.7 (±5.5)     | –21.6 (±7.1) | 0.25    |
| RVLS mid, % (±SD)     | –27.6 (±4.1)     | –26.3 (±5.7) | 0.04    |
| RVLS basal, % (±SD)   | –26.2 (±4.3)     | –24.8 (±6.4) | 0.06    |
| LVLS anterior basal, % (±SD) | –17.9 (±3.3) | –17.2 (±3.9) | 0.18    |
| LVLS anterior mid, % (±SD) | –18.5 (±3.4) | –17.6 (±3.8) | 0.08    |
| LVLS anterior apical, % (±SD) | –20.1 (±4.9) | –19.9 (±5.2) | 0.75    |
| LVLS anterolateral basal, % (±SD) | –17.4 (±3.3) | –15.7 (±4.8) | 0.005   |
| LVLS anterolateral mid, % (±SD) | –17.3 (±3.4) | –16.3 (±4.8) | 0.04    |
| LVLS inferolateral basal, % (±SD) | –17.9 (±3.6) | –15.4 (±6.7) | <0.001  |
| LVLS inferolateral mid, % (±SD) | –17.8 (±2.9) | –16.5 (±4.1) | 0.02    |
| LVLS lateral apical, % (±SD) | –19.2 (±3.6) | –19.3 (±3.8) | 0.87    |
| LVLS inferior basal, % (±SD) | –19.3 (±3.1) | –18.6 (±3.5) | 0.16    |
| LVLS inferior mid, % (±SD) | –21.0 (±2.5) | –19.9 (±3.2) | 0.004   |
| LVLS inferior apical, % (±SD) | –24.0 (±3.8) | –23.3 (±4.8) | 0.22    |
| LVLS inferoseptal basal, % (±SD) | –16.2 (±2.4) | –15.6 (±3.2) | 0.09    |
| LVLS inferoseptal mid, % (±SD) | –19.1 (±2.5) | –18.5 (±2.8) | 0.11    |
| LVLS anteroseptal basal, % (±SD) | –16.4 (±3.0) | –15.8 (±3.9) | 0.15    |
| LVLS anteroseptal mid, % (±SD) | –18.8 (±3.8) | –18.8 (±3.8) | 0.94    |
| LVLS septal apical, % (±SD) | –21.4 (±3.9) | –21.7 (±4.1) | 0.57    |

**Table 1.** Segmental RVLS and LVLS values in healthy individuals and BrS patients. Comparison was performed by Student’s t-test. 
BrS = Brugada syndrome, LVLS = left ventricular longitudinal strain, RVLS = right ventricular longitudinal strain, SD = standard deviation.

![Fig. 1. Speckle tracking segments. Bullseye plot of the 16 left ventricular and 3 right ventricular free wall segments.](image-url)
wall and 6 right ventricle segments, was calculated in all patients, as a measure of contraction heterogeneity (Fig. 2).

Echocardiographic data were reported for specific subgroups of Brugada syndrome patients. First, we compared patients who presented a spontaneous type 1 electrocardiogram pattern with patients who were diagnosed based on a drug-induced type 1 pattern (Table 2).

Secondly, we compared patients in whom a sustained ventricular arrhythmia could be induced during electrophysiological study compared to patients in whom no ventricular arrhythmia could be induced (Table 3). A total of 168 patients (96%) underwent electrophysiological testing.

Table 2
Demographic and echocardiographic parameters for LV and RV function. Comparison between BrS patients with drug-induced vs. spontaneous type 1 ECG using Student’s t-test, Mann-Whitney U test, or chi-square test as appropriate.

| Demographics | BrS with drug-induced type 1 ECG, n = 133 | BrS with spontaneous type 1 ECG, n = 42 | p-value |
|---------------|------------------------------------------|---------------------------------------|---------|
| Age, years (IQR) | 47 (33–56) | 47 (38–57) | 0.32 |
| Women, n (%) | 73 (55) | 15 (36) | 0.03 |
| TTE | | | |
| LV EF, % (±SD) | 58 (±7) | 58 (±6) | 0.82 |
| LV GLS, % (±SD) | −18.2 (±2.5) | −18.0 (±2.5) | 0.74 |
| LV MD, ms (±SD) | 36 (±11) | 42 (±11) | 0.002 |
| RVOTd, mm (IQR) | 33 (30–36) | 33 (29–36) | 0.90 |
| RVOTd, mm (IQR) | 21 (18–25) | 23 (19–24) | 0.30 |
| TAPSE, mm (±SD) | 24 (±4) | 24 (±7) | 0.83 |
| RV FAC, % (IQR) | 44 (36–49) | 40 (33–46) | 0.12 |
| RVLS, % (IQR) | −24.4 (±5.4) | −24.4 (±5.5) | 0.95 |
| RV MD, ms (IQR) | 21 (13–38) | 31 (18–49) | 0.04 |
| RVFW MD, ms (IQR) | 15 (8–24) | 18 (7–37) | 0.27 |

Table 2. Demographic and echocardiographic parameters for LV and RV function. Comparison between BrS patients with drug-induced vs. spontaneous type 1 ECG pattern using Student’s t-test, Mann-Whitney U test, or chi-square test as appropriate. BrS = Brugada syndrome, FAC = fractional area change, GLS = global longitudinal strain, LV = left ventricle, LVEF = left ventricle ejection fraction, MD = mechanical dispersion, RV = right ventricle, RVFW = right ventricle free wall, RVLS = right ventricular longitudinal strain, RVOTd = distal right ventricular outflow tract diameter, RVOTp = proximal right ventricular outflow tract diameter, TAPSE = tricuspid annular plane systolic excursion, TTE = transthoracic echocardiography.
2. Experimental design, materials, and methods

2.1. Study population

Brugada syndrome patients were recruited from the database of the University Hospital of Brussels. All had been diagnosed with Brugada syndrome based either on a spontaneous or drug induced ST segment elevation with a type 1 morphology of ≥2 mm in 1 or more leads among the right precordial leads (V1–V2) positioned in the second, third, or fourth intercostal space [1,2]. Included patients were at least 18 years old. We excluded patients with a history of ischemic or structural heart disease. We also excluded patients with atrial fibrillation or pacing during transthoracic echocardiography (TTE) or with insufficient image quality for speckle tracking analysis of both left and right ventricle, defined as inappropriate tracking of 2 or more segments on a single view.

Healthy controls with similar age and sex distribution were recruited among hospital employees and their family members. Written informed consent was obtained from all subjects. This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of UZ Brussel.

2.2. Echocardiography

TTE was performed using a commercial cardiac ultrasound system (Vivid 9; GE Vingmed Ultrasound, Horten, Norway), equipped with a 2D broad-band M3S transducer (2.5 MHz). In each patient standard parastrernal long- and short-axis images, apical 4-, 2- and 3-chamber views and a RV focused 4-chamber view were acquired [14]. Lead II was used for ECG recordings. Loops of 3 consecutive heart beats at >50 frames per second were digitally stored for offline analysis (EchoPac, version 201, GE Vingmed Ultrasound, Horten, Norway).

The LV end-diastolic volume (LVEDV) and LV end-systolic volume (LVESV) were measured and the ejection fraction (EF) was calculated by modified Simpson’s biplane method. Tricuspid annular plane systolic excursion (TAPSE) was obtained by M-mode through the tricuspid annulus on the 4-chamber view. RV outflow tract (RVOT) proximal and distal diameters were measured from the parasternal

| Demographic and echocardiographic parameters for LV and RV function. Comparison between BrS patients without inducibility of VT or VF during electrophysiological testing vs. inducible BrS patients using Student’s t-test, Mann-Whitney U test, or chi-square test as appropriate. BrS = Brugada syndrome, FAC = fractional area change, GLS = global longitudinal strain, LV = left ventricle, LVEF = left ventricle ejection fraction, MD = mechanical dispersion, RV = right ventricle, RVFW = right ventricle free wall, RVLS = right ventricular longitudinal strain, RVOTd = distal right ventricular outflow tract diameter, RVOTp = proximal right ventricular outflow tract diameter, TAPSE = tricuspid annular plane systolic excursion, TTE = transthoracic echocardiography, VF = ventricular fibrillation, VT = ventricular tachycardia. | BrS not inducible, n = 141 | BrS inducible, n = 27 | p-value |
|---|---|---|---|
| **Demographics** | | | |
| Age, years (IQR) | 47 (33–56) | 47 (38–57) | 0.32 |
| Women, n (%) | 75 (53) | 10 (37) | 0.12 |
| **TTE** | | | |
| LV EF, % (±SD) | 58 (±7) | 58 (±7) | 0.89 |
| LV GLS, % (±SD) | −18.1 (±2.5) | −18.4 (±2.4) | 0.58 |
| LV MD, ms (±SD) | 37 (±12) | 42 (±10) | 0.04 |
| RVOTp, mm (IQR) | 33 (29–36) | 34 (21–36) | 0.54 |
| RVOTd, mm (IQR) | 22 (17–24) | 22 (19–26) | 0.25 |
| TAPSE, mm (±SD) | 24 (±5) | 25 (±4) | 0.32 |
| RV FAC, % (IQR) | 42 (35–48) | 40 (34–51) | 0.88 |
| RVLS, % (IQR) | −24.8 (±2.4) | −23.1 (±5.5) | 0.95 |
| RV MD, ms (IQR) | 23 (14–41) | 22 (17–36) | 0.90 |
| RVFW MD, ms (IQR) | 15 (8–25) | 19 (10–27) | 0.34 |

Table 3
short-axis view. End-diastolic and end-systolic RV area (RVA) were obtained from the RV focused 4-chamber view and fractional area change (FAC) was calculated [15].

Speckle tracking analysis was performed on the 3 apical views for the LV and on the RV focused 4-chamber view for the RV [14,16]. When necessary, the automated region of interest was adjusted to optimise tracking. GLS was defined as the mean of the peak systolic strain in the 16 LV segments and RV longitudinal strain (RVLS) from the 3 RV free wall segments (Fig. 1). The time to peak myocardial longitudinal strain in each segment was measured as the time from onset of the QRS complex on the ECG to maximum myocardial shortening. MD was defined as the standard deviation of the time to peak in respectively the 16 LV segments, the 6 RV segments and the 3 RV free wall segments (Fig. 2) [17,18].

2.3. Drug-challenge

Ajmaline (1 mg/kg) was administered intravenously over a 5-min period to unmask the diagnostic type 1 electrocardiogram pattern in case of non-diagnostic baseline electrocardiogram. The test was considered positive if type 1 ECG appeared in ≥1 right precordial leads. The drug infusion was discontinued if QRS prolongation exceeded 30%, frequent premature ventricular beats or type 1 Brugada ECG occurred or development of high-degree atrio-ventricular block.

2.4. Electrophysiological study

Electrophysiological study protocol consisted of a single site of stimulation at the right ventricular apex, three basic pacing cycles (600, 500, and 430 ms), and introduction of up to 3 ventricular premature beats down to a minimum of 200 ms. A patient was considered inducible if a sustained (≥30 seconds) ventricular fibrillation or ventricular tachycardia was induced.

2.5. Statistics

Continuous data was presented as mean ± standard deviation or median with interquartile range (IQR). Categorical data was presented as number (%). Comparisons were performed using T-test, Mann-Whitney U test, χ2 or Fischer’s exact test as appropriate.

Statistical analysis was performed using SPSS version 24.0 (SPSS Inc., Chicago, IL, USA).

Acknowledgments

We thank all study participants for their time and effort.

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.dib.2019.104330.

References

[1] S.G. Priori, A.A. Wilde, M. Horie, et al., HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACEs, and AEPC in June 2013, Heart Rhythm 10 (12) (2013) 1932–1963, https://doi.org/10.1016/j.hrthm.2013.05.014.
[2] S.G. Priori, C. Blomstrom-Lundqvist, A. Mazzanti, et al., ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC) endorsed by:
association for european paediatric and congenital cardiology (AEPC), Europace. 2015 17 (11) (2015) 1601–1687, https://doi.org/10.1093/europace/euv319.

[3] O. Catalano, S. Antonaci, G. Moro, et al., Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities, Eur. Heart J. 30 (18) (2009) 2241–2248, https://doi.org/10.1093/eurheartj/ehp252.

[4] B. Gray, G.K. Gnanappa, R.D. Bagnall, et al., Relations between right ventricular morphology and clinical, electrical and genetic parameters in Brugada Syndrome, PLoS One 13 (4) (2018), https://doi.org/10.1371/journal.pone.0195594.e0195594.

[5] K. Nademanee, H. Raju, S.V. de Noronha, et al., Fibrosis, connexin-43, and conduction abnormalities in the Brugada syndrome, J. Am. Coll. Cardiol. 66 (18) (2015) 1976–1986, https://doi.org/10.1016/j.jacc.2015.08.862.

[6] T. Papavassiliu, C. Wolpert, S. Fluchter, et al., Magnetic resonance imaging findings in patients with Brugada syndrome, J. Cardiovasc. Electrophysiol. 15 (10) (2004) 1133–1138, https://doi.org/10.1046/j.1540-8167.2004.03681.x.

[7] B. Rudic, R. Schimpf, C. Veltmann, et al., Brugada syndrome: clinical presentation and genotype-correlation with magnetic resonance imaging parameters, Europace 18 (9) (2016) 1411–1419, https://doi.org/10.1093/europace/euv300.

[8] M. Takagi, N. Aihara, S. Kuribayashi, et al., Localized right ventricular morphological abnormalities detected by electron-beam computed tomography represent arrhythmogenic substrates in patients with the Brugada syndrome, Eur. Heart J. 22 (12) (2001) 1032–1041, https://doi.org/10.1053/euhj.2001.2424.

[9] M. Iacoviello, C. Forleo, A. Puzzovivo, et al., Altered two-dimensional strain measures of the right ventricle in patients with Brugada syndrome and arrhythmogenic right ventricular dysplasia/cardiomyopathy, Eur. J. Echocardiogr. 12 (10) (2011) 773–781, https://doi.org/10.1093/eurheartj/ehr055.

[10] S.C. Van Malderen, D. Kerkhove, D.A. Theuns, et al., Prolonged right ventricular ejection delay identifies high risk patients and gender differences in Brugada syndrome, Int. J. Cardiol. 191 (2015) 90–96, https://doi.org/10.1016/j.ijcard.2015.04.243.

[11] R. Bastiaenen, A.T. Cox, S. Castellletti, et al., Late gadolinium enhancement in Brugada syndrome: a marker for subtle underlying cardiomyopathy? Heart Rhythm 14 (4) (2017) 583–589, https://doi.org/10.1016/j.hrthm.2016.12.004.

[12] O.A. Smiseth, H. Torp, A. Opdahl, K.H. Haugaa, S. Urheim, Myocardial strain imaging: how useful is it in clinical decision making? Eur. Heart J. 37 (15) (2016) 1196–1207, https://doi.org/10.1093/eurheartj/ehw529.

[13] E. Scheirlynck, S. Van Malderen, A. Motoe, et al., Contraction alterations in Brugada syndrome; association with life-threatening ventricular arrhythmias, Int. J. Cardiol. (2019), https://doi.org/10.1016/j.ijcard.2019.06.074.

[14] L.P. Badano, T.J. Kolas, D. Muraru, et al., Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging, Eur. Heart J. Cardiovasc. Imaging (2018), https://doi.org/10.1093/ehjci/jey042.

[15] L.G. Rudski, W.W. Lai, J. Allo, et al., Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American society of echocardiography endorsed by the american society of cardiovascular disease and the canadian society of echocardiography, J. Am. Soc. Echocardiogr. 23 (7) (2010) 685–713, https://doi.org/10.1016/j.echo.2010.05.010, quiz 86-8.

[16] J.U. Voigt, G. Pedrizzetti, P. Lysyansky, et al., Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging, Eur. Heart J. Cardiovasc. Imaging 16 (1) (2015) 1–11, https://doi.org/10.1093/ehjci/jeu184.

[17] S.I. Sarvari, K.H. Haugaa, O.G. Anfinsen, et al., Right ventricular mechanical dispersion is related to malignant arrhythmias: a study of patients with arrhythmogenic right ventricular cardiomyopathy and subclinical right ventricular dysfunction, Eur. Heart J. 32 (9) (2011) 1089–1096, https://doi.org/10.1093/eurheartj/ehq069.

[18] K.H. Haugaa, B.L. Grenne, C.H. Eek, et al., Strain echocardiography improves risk prediction of ventricular arrhythmias after myocardial infarction, JACC Cardiovasc. Imaging 6 (8) (2013) 841–850, https://doi.org/10.1016/j.jcmg.2013.03.005.